MedicineChemistry
A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 2. Considering host-specific and product-specific factors impacting immunogenicity
A. Rosenberg, A. Worobec
tlooto Summary
For protein therapeutics, immunogenicity testing should be conducted from the earliest stages of product development to establish whether the molecule is likely to be safe and effective in the environment.
Abstract
For protein therapeutics, immunogenicity testing should be conducted from the earliest stages of product development .
Citation format
ROSENBERG, A.; WOROBEC, A. A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 2. considering host-specific and product-specific factors impacting immunogenicity. BIOPHARM INTERNATIONAL, 2004, 17: 34–42.